<?xml version="1.0" encoding="UTF-8"?>
<ack id="ack0001">
 <sec id="sec0015a">
  <title>Funding</title>
  <p id="para0043">This paper was sponsored by the Immuno-Gene Therapy of the International Society for Cell and Gene Therapy. V.B. is supported by Fondazione Cariverona (ENACT project) and Fondazione TIM. M.C. and J.J.B. acknowledge support of the NIH Cancer Center Support Grant P30 CA008748.</p>
 </sec>
 <sec id="sec0016a">
  <title>Declaration of Competing Interest</title>
  <p id="para0046">PJH: Stock, other ownership interests, and serves on the board of directors of Mana Therapeutics. Intellectual property related to virus-specific T cells. BL: Stock and other ownership interests in Tmunity Therapeutics; honoraria: Novartis, Terumo, AstraZeneca; consulting or advisory role: Brammer Bio/ThermoFisher Viral Vector services, Avectas, Immuneel, Ori Biotech and Vycellix. VB: BioNTech AG, patent and research collaboration; Ganymed Pharmaceuticals AG, research collaboration; Xios Therapeutics, Scientific Advisory Board; Codiak BioSciences, scientific advisory board; Incyte Corporation, research collaboration. CMB: Stock, Scientific Advisory Board, other ownership interests in Mana Therapeutics. Stock, Cogen Immune Medicine and Neximmune; stock, board of directors, Cabaletta Bio; stock, Scientific Advisory Board, Catamaran Bio; Intellectual property related to virus-specific T cells and NK cells. JJB: DMC member/chair (consulting); advanced clinical consulting: Avrobio, Takeda, Omeros, Bluebird Bio, BlueRock, Race Oncology; grants: Sanofi (unrestrictedÂ grant for clinical trial). The other authors have no commercial, proprietary, or financial interest in the products or companies described in this article.</p>
 </sec>
 <sec id="sec0017">
  <title>Author Contributions</title>
  <p id="para0044">Conception and design of the study: MC, JJB, PH. Analysis and interpretation of data: MC, PH, JJB, BL, RC, PR, VB, DW, CB. Drafting or revising the manuscript: MC, PH, JJB, BL, RC, PR, VB, DW, CB. All authors have approved the final article.</p>
 </sec>
 <sec id="sec0019">
  <title>Acknowledgments</title>
  <p id="para0045">The authors thank the Immuno-Gene Therapy Committee of the International Society for Cell and Gene Therapy (ISCT) for sponsoring this article. We also recognize Dr. Alexey Bersenev for providing the open-access COVID-19 clinical trial database.</p>
 </sec>
</ack>
